Study #2024-0308
ZAnzalintinib Neoadjuvant EValuation In Thyroid Oncology (ZANEVO)
MD Anderson Study Status
Enrolling
Treatment Agent
Zanzalintinib
Description
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neoadjuvant Treatment, Thyroid Cancer
Study phase:
Phase II
Physician name:
Mark Zafereo
Department:
Head & Neck Surgery
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.